IQ-AI Limited IB's Software featured in award-winning article (6675G)

TIDMIQAI

RNS Number : 6675G

IQ-AI Limited

18 March 2020

IQ-AI Ltd

("IQ-AI" or the "Company")

Study Using Imaging Biometrics' Brain Tumor Image Analysis Software Wins 2019's Top Award from the American Journal of Neuroradiology

Imaging Biometrics, LLC, (IB), a wholly-owned subsidiary of IQ-AI and a recognized industry leader in quantitative imaging analysis for brain tumor diagnosis and treatment, is proud to announce its software was featured in the top-award-winning article in the March 2020 issue of the American Journal of Neuroradiology (AJNR). AJNR, a publication of the American Society of Neuroradiology, presented the article with the Lucien Levy Award, recognizing it as the best original research paper accepted in 2019.

The article, "Performance of Standardized Relative CBV for Quantifying Regional Histologic Tumor Burden in Recurrent High-Grade Glioma: Comparison against Normalized Relative CBV Using Image-Localized Stereotactic Biopsies" (http://www.ajnr.org/content/early/2020/03/12/ajnr.A6486), showcases a study led by Dr. Leland Hu, MD (Mayo Clinic in Arizona) that demonstrates the superior ability of IB's vascular mapping software to identify and distinguish recurrent high-grade brain tumor from benign treatment effects. These treatment effects occur frequently in patients undergoing standard chemoradiation treatment after surgery, and typically resolve over a period of several months post-treatment. However, these tissues appear similar on standard MRI creating a major challenge for treating physicians. As described, IB's exclusive software, which provides a measurement of tumor burden within each image voxel, addresses this need.

IB's software also streamlines workflow by eliminating time-consuming manual processing steps, delivering the power of advanced research analysis in a clinical setting. Dr. Hu's study demonstrates that IB's image Standardization algorithm is key to making this possible. Further, the study shows that IB's vascular mapping is a reliable solution for MR images from multiple vendors.

"Our relative cerebral blood volume maps have the potential to aid clinical decision-making before surgery, during recovery, and during follow-up treatment," said Michael Schmainda, CEO of IB. "This study not only proves the clinical relevance of vascular mapping in tumors for monitoring treatment response, it also highlights the workflow benefits IB provides through automation. Our solutions are built on decades of specialized experience in brain tumor imaging, which allows us to create fully automated methods that are both repeatable and robust. This optimized workflow certainly has the potential of becoming the consensus methodology, as the paper cites," Schmainda added.

The Directors of the Company accept responsibility for the contents of this announcement.

-ENDS-

For further information, please contact:

 
 IQ-AI Limited 
  Trevor Brown/Vinod Kaushal/Qu Li 
  Tel: [phone] 
---------------------------------------------------------- 
 Peterhouse Capital Limited (Financial Adviser and Broker) 
  Lucy Williams/Heena Karani 
  Tel: [phone] 
---------------------------------------------------------- 
 

About IQ-AI Ltd (iq-al.ltd) IQ-AI, Ltd, the parent company of Imaging Biometrics(R) and StoneChecker(TM), is focused on providing advanced and state-of-the-art medical software and related services. Imaging Biometrics develops and provides visualization and analytical solutions enabling clinicians to better diagnose and treat diseases with greater confidence. Through close collaboration with researchers and clinicians, sophisticated advancements are translated into platform-independent software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualization software seamlessly integrates into routine workflows. Please visit www. imagingbiometrics.com for more information.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

STRJPMITMTJBBBM

(END) Dow Jones Newswires

March 18, 2020 10:34 ET (14:34 GMT)